Differential induction of gene expression may explain differences in reported adverse event profiles between the FGFR-inhibitors derazantinib and erdafitinib: An analysis in safety relevant normal tissues from urothelial cancer (UC) patient-derived mouse xenograft (PDX) models

被引：1

作者：

McSheehy, P. ^{[1
]}

Guo, J. ^{[2
]}

Beebe, K. ^{[2
]}

Eisner, J. R. ^{[2
]}

Anderson, S. ^{[3
]}

Braun, S. ^{[3
]}

Engelhardt, M. ^{[3
]}

Kellenberger, L. ^{[1
]}

Lane, H. ^{[1
]}

Milburn, M. ^{[2
]}

机构：

[1] Basilea Pharmaceut Int Ltd, Res, Basel, Switzerland

[2] GeneCentr Therapeut Inc, Res, Durham, NC USA

[3] Basilea Pharmaceut Int Ltd, Dev, Basel, Switzerland

来源：

关键词：

D O I：

10.1016/j.annonc.2020.08.1352

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1960P

引用

页码：S1103 / S1104

页数：2